Figure 1
![Figure 1. Bortezomib decreases proliferation and sensitizes RENCA tumor cells to syngeneic NK-cell lysis, but does not induce tumor apoptosis or alter cell-surface expression of MHC class I, DR5, Fas, Rae-1, or ICAM-1. RENCA or LLC1 tumor cells were treated with 20 nM bortezomib for 18 hours and were analyzed for (A) syngeneic BALB/c or C57BL/6 NK cell lysis in a 4-hour 51Cr release assay; (B) surface expression of MHC class I, Fas, DR5, Rae-1, Mult-1, H60, and ICAM-1 (x-axis shows log fluorescence); (C) proliferation (after 72 hours of bortezomib treatment [0.5-20 nM]);and (D) induction of apoptosis (assessed by staining for annexin V and propidium iodide). y- and x-axes show log fluorescence. Error bars in panels A and C depict SD.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/113/24/10.1182_blood-2008-11-190421/4/zh80180934310001.jpeg?Expires=1735550996&Signature=0obsB9nBR~LYU5JbG2e2CSz6BZq-lHKVFXrR4AFLqueBpgnis7F5ncn6fc1o8uONTowPBWlnT-59TzejlVFxRs7OJ5IXKInpa5yht7ZwH6njutmi7OkTx7b58lxJACSSDI1IiCRr~u3vH0NqsapfzdIvPNb-sevkub-tnNVYjiyc934sHUrEvNjNIe~j3jxd9OecxZ31HZ43mNEyc4MZhtdVxJp81fJ4ijO-4oWBv88xxA23NZuSi-zCpPa7n8uimfpP~-RrtYzHXWKqTFurepyWkH3pHXehTJvO0o~GW9Pb7LVMhufF6IK7-e15gJCg6q1ArMLZToX0mOQOJVzHmg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Bortezomib decreases proliferation and sensitizes RENCA tumor cells to syngeneic NK-cell lysis, but does not induce tumor apoptosis or alter cell-surface expression of MHC class I, DR5, Fas, Rae-1, or ICAM-1. RENCA or LLC1 tumor cells were treated with 20 nM bortezomib for 18 hours and were analyzed for (A) syngeneic BALB/c or C57BL/6 NK cell lysis in a 4-hour 51Cr release assay; (B) surface expression of MHC class I, Fas, DR5, Rae-1, Mult-1, H60, and ICAM-1 (x-axis shows log fluorescence); (C) proliferation (after 72 hours of bortezomib treatment [0.5-20 nM]);and (D) induction of apoptosis (assessed by staining for annexin V and propidium iodide). y- and x-axes show log fluorescence. Error bars in panels A and C depict SD.
